Alector price target lowered to $35 from $41 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Alector to $35 from $41 and keeps a Buy rating on the shares. In addition to the INFRONT-3 and the INVOKE-2 trial, Alector has swiftly moved forward with another AD trial, PROGRESS-AD, notes the firm, which has revised its operating expense assumptions given the development programs surrounding AL101, AL002, and the ABC platform.